Fresh analysis suggests that patients who discontinue new GLP-1 drugs like semaglutide or tirzepatide can put back on reduced body mass far faster than those who stop traditional diet and exercise regimens.
Research printed in a prominent health publication demonstrates that while obese individuals can lose a large proportion of their total mass while using the jabs, the weight returns at an average rate of nearly a kilo each month once they quit.
"Individuals buying such treatments must be cognizant of the potential of quick weight regain when the therapy ends," cautioned expert Dr. Susan Jebb.
Such speed of regain suggests a return to starting weight within about a year and a half.
Comparing Therapies
The analysis, which examined dozens of studies involving over 9,000 of patients, contrasted the effects of these new drugs with conventional dieting.
Researchers note that individuals who lose weight through diet and exercise typically see a less rapid creep back—approximately 100 grams monthly—post-intervention.
Explaining the Quick Rebound
Doctors propose the mode of action of the jabs explains the amplified weight return.
GLP-1 drugs copy a body's own chemical called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Long-term administration of GLP-1 levels several times higher than normal could lead to the body to generate a reduced amount of its endogenous hormone, and could diminish responsiveness to its actions," said Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this medication results in appetite is no longer kept in check, making excessive eating much more probable."
An Ongoing Issue?
The NHS suggest the injections for individuals with obesity-related medical conditions, accompanied by recommended lifestyle changes.
Many experts contend that, given the likelihood of weight regain, the treatment should be considered long-term.
This opinion is echoed by drug manufacturers, who state that the findings "emphasize the long-term character of excess weight," akin to managing diseases like diabetes.
Patient Experiences
Individuals who have discontinued the jabs report a intense resurgence of hunger.
"It felt as if a switch flipping and you're instantly extremely hungry," described one woman.
The struggle is exacerbated if patients have not developed permanent dietary or behavioural modifications during therapy.
Significant Use
Survey data indicate that a significant number of people in the UK have used these injections in the last 12 months, with demand remaining high.
- Adoption is greater among women than men.
- The middle-aged demographic shows the greatest usage rates.
- A large proportion obtain the medications through private healthcare rather than public health services.
Finally, clinicians emphasize that while these medications are powerful tools for shedding pounds, they are not a standalone cure and long-term success hinges on combined behavioural changes.
